Biomanufacturing Excellence Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Creates a federally supported National Biopharmaceutical Manufacturing Center of Excellence to accelerate manufacturing innovation, workforce development, and supply-chain resilience.
Who Benefits and How
Biopharmaceutical manufacturers, research institutions, and workforce partners could receive a new center, federal support, and training resources to scale domestic production.
Who Bears the Burden and How
Federal agencies would need to fund, select, and oversee the center and coordinate its objectives around national, health, and economic security.
Key Provisions
- States findings and a sense of Congress supporting a national biopharmaceutical manufacturing center of excellence.
- Directs NIST to make a competitive grant or other transaction agreement to establish and operate the center.
- Tasks the center with manufacturing innovation, standards, workforce development, and supply-chain strengthening.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Creates a federally supported National Biopharmaceutical Manufacturing Center of Excellence to accelerate manufacturing innovation, workforce development, and supply-chain resilience.
Key Policy Areas
Healthcare, Science & Space, Government Operations
Primary Purpose
Creates a federally supported National Biopharmaceutical Manufacturing Center of Excellence to accelerate manufacturing innovation, workforce development, and supply-chain resilience.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Biopharmaceutical manufacturers, research institutions, and workforce partners
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal agencies funding and overseeing the center
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Coons (for himself and Mr. Budd) introduced the following …
Read twice and referred to the Committee on Commerce, Science, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biopharmaceutical manufacturers, research institutions, and workforce partners participating in the center
Federal agencies funding and overseeing the center
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology